Hepatitis C News and Research

Latest Hepatitis C News and Research

Androgen receptors promote hepatitis B virus in growth and development of hepatoma cells

Dr. Ming-Heng Wu of the Institute of Basic Medical Sciences at National Cheng Kung University (NCKU), Taiwan, in collaboration with Prof. Chawnshang Chang's laboratory of University of Rochester (UR), United States, have discovered that androgen receptors (AR) can promote hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus (HBV) RNA transcription.

20 May 2010

Pennsylvania Department of Health recommends hepatitis A and B vaccination for children and adults at risk

The Pennsylvania Department of Health recommends immunization of children and adults at the highest risk for hepatitis during "Hepatitis Awareness Month" and "World Hepatitis Day" on May 19.

20 May 2010

Texas prison health care system to lay off nearly 12 percent of workforce

The state institution that provides health services to Texas state prisoners will lay off 363 workers because of budget cuts. "The announcement is expected to ramp up concerns over a growing state budget crisis — and how Texas can continue to pay for a massive prison health care system that gobbles tens of millions of additional taxpayer dollars each year.

20 May 2010

ABBOTT PRISM Chagas test receives FDA approval

Abbott received Biologic License Application (BLA) approval from the United States Food and Drug Administration (FDA) for the ABBOTT PRISM Chagas test. The test is a fully automated blood screening assay that can detect antibodies to Trypansoma cruzi (T. cruzi), a parasite found only in the Americas and most commonly acquired through contact with the blood-sucking triatomine or "kissing bug."

19 May 2010

Vaccinations recommended for adults

Yearly vaccinations aren't just for kids any more. You probably heard a lot about a seasonal or H1N1 flu shot last fall, but you should know that a battery of other adult vaccinations might also become part of your health care routine. Pneumonia and shingles vaccines are preventive-care essentials for older adults, and meningitis and tetanus shots are now college rites of passage. Even the vaccines of childhood—measles, mumps and rubella, and whooping cough—are recommended for adults who missed out in their younger years.

19 May 2010

New test to detect HBV receives regulatory approval for use in the European Union

An inexpensive new test for the detection of Hepatitis B virus has been given regulatory approval for use in the European Union. The test, developed with support from the Wellcome Trust, delivers accurate results while-you-wait, enabling doctors to take immediate action on health decisions.

19 May 2010

Where are Australia’s missing hepatitis C cases?

Around 90% of those infected have not received treatment, despite the potential for cure, a report to coincide with National Hepatitis Week shows

18 May 2010

Underwriters exercise overallotment option to purchase additional 480,000 shares in Pharmasset offering

Pharmasset, Inc. announced today the underwriters of its recent stock offering have exercised their option to purchase an additional 480,000 shares of common stock. The net proceeds to Pharmasset, Inc., after deducting the underwriting discount, from the sale of these additional shares are expected to be approximately $13.2 million.

18 May 2010

Immunizations Across the Lifespan campaign launched to educate adults on current vaccinations

The Pennsylvania Department of Health is urging adults to ensure they are up-to-date on all needed vaccinations.

18 May 2010

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010.

18 May 2010

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

NanoViricides, Inc., announced that it has signed a Research Agreement with the University of California, San Francisco for testing of its anti-HIV drug candidates. Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.

17 May 2010

Biostar Pharmaceuticals first-quarter 2010 revenues increase 66.0% to $12.4 million

Biostar Pharmaceuticals, Inc., a Xianyang- based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced financial results of the first quarter ended March 31, 2010.

17 May 2010

Inhibitex commences trials on INX-189 for treatment of Hepatitis C infections

The first clinical trials have started on a new investigational drug, discovered by researchers at Cardiff University, which is being developed to treat infections caused by Hepatitis C virus.

15 May 2010

CSL Behring donates life-saving medicines to assist earthquake victims in Haiti

Direct Relief International announced today that CSL Behring has donated life-saving medicines valued at more than $100,000 to assist earthquake victims in Haiti who are at risk of tetanus or hepatitis B infections. The products will be used in clinics at Hopital Albert Schweitzer in Deschapelles.

14 May 2010

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

NanoViricides, Inc., reports that it has signed a research and development agreement with Dr. Ken S. Rosenthal's laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

14 May 2010

Inhibitex reports net loss of $4.8M for first-quarter 2010

Inhibitex, Inc. today announced its financial results for the first quarter ended March 31, 2010. The Company also announced that it has initiated a Phase I single ascending dose trial of INX-189, its lead HCV nucleotide polymerase inhibitor, in healthy volunteers under an Investigational New Drug application with the U.S. Food and Drug Administration.

14 May 2010

Report examines vaccine costs, access in low-income countries

A recent report by Medecins Sans Frontieres (MSF) and Oxfam International warns "that the global campaign to vaccinate children in poor countries is being hampered by high prices and is facing an acute funding crisis," BMJ News reports.

14 May 2010

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010.

14 May 2010

Pharmasset prices underwritten public offering of common stock

Pharmasset, Inc. announced today the pricing of an underwritten public offering of 3,200,000 shares of its common stock at an offering price of $29.00 per share. Pharmasset expects to receive net proceeds, after deducting the underwriting discount and estimated offering expenses, of approximately $87.9 million.

14 May 2010

MitoSciences awarded $590,000 to support development of companion diagnostic tests for antiviral drugs

MitoSciences announces that it has just been awarded $590,000 by the National Institutes of Health to support the development of companion diagnostic tests for antiviral drugs. The award was made after competitive scientific review and was issued under The American Recovery and Reinvestment Act of 2009.

14 May 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Androgen receptors promote hepatitis B virus in growth and development of hepatoma cells

Pennsylvania Department of Health recommends hepatitis A and B vaccination for children and adults at risk

Texas prison health care system to lay off nearly 12 percent of workforce

ABBOTT PRISM Chagas test receives FDA approval

Vaccinations recommended for adults

New test to detect HBV receives regulatory approval for use in the European Union

Where are Australia’s missing hepatitis C cases?

Underwriters exercise overallotment option to purchase additional 480,000 shares in Pharmasset offering

Immunizations Across the Lifespan campaign launched to educate adults on current vaccinations

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

Biostar Pharmaceuticals first-quarter 2010 revenues increase 66.0% to $12.4 million

Inhibitex commences trials on INX-189 for treatment of Hepatitis C infections

CSL Behring donates life-saving medicines to assist earthquake victims in Haiti

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

Inhibitex reports net loss of $4.8M for first-quarter 2010

Report examines vaccine costs, access in low-income countries

Sinovac Biotech's sales for first-quarter 2010 decrease 32% to $4.4M

Pharmasset prices underwritten public offering of common stock

MitoSciences awarded $590,000 to support development of companion diagnostic tests for antiviral drugs

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in